Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
Eric L. Simpson(Oregon Health & Science University), David M. Pariser(Eastern Virginia Medical School), Usha G. Mallya, Matt Reaney(Sanofi (United Kingdom)), T. Michelle Brown(RTI Health Solutions), Min Yang(Analysis Group (United States)), Lauren Nelson(RTI Health Solutions), Isabelle Guillemin, Abhijit Gadkari(Regeneron (United States)), Laurent Eckert(Sanofi (France)), Puneet Mahajan(Research Triangle Park Foundation), Mark Boguniewicz(University of Colorado Denver)
Cited by 0
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2014|1.2k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k